BackYD Bio Limited Ordinary Shares Overview

YD Bio Limited Ordinary Shares Other Current Liabilities

YD Bio Limited Ordinary Shares's other current liabilities is $1.2M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.19M
443.81% YoYΔ $973925.00 vs prior year quarter

Peer trimmed avg / median

Loading

YD Bio Limited Ordinary Shares Other Current Liabilities History

Loading

YD Bio Limited Ordinary Shares vs. peers: Other Current Liabilities Comparison

Loading

YD Bio Limited Ordinary Shares Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

YD Bio Limited Ordinary Shares (YDES) FAQ

YD Bio Limited Ordinary Shares's other current liabilities stands at $1.2M as of December 2025. That compares with $220K in the prior-year period — up 443.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

YD Bio Limited Ordinary Shares reported $1.2M in other current liabilities versus $220K a year earlier — a 443.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $220K in the prior-year period — up 443.8% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how YD Bio Limited Ordinary Shares's other current liabilities evolved across reporting periods, while the comparison chart places YDES next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. YD Bio Limited Ordinary Shares's reading of $1.2M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.